MedImmune, AstraZeneca's biologics research and development subsidiary, entered into a $250 million licensing agreement with Allergan for the global rights to the MEDI2070.
Here are four things to know.
- MEDI2070 is an anti-inflammatory drug undergoing clinical trials for the treatment of Crohn's disease and ulcerative colitis.
- Parsippany-Troy Hills, N.J.-based Allergan purchased the exclusive global rights to MEDI2070 for an upfront payment of $250 million, with the potential for future milestone payments of up to $1.27 billion.
- Gaithersburg, Md.-based MedImmune is developing MEDI2070 through a collaboration agreement with Amgen, headquartered in Thousand Oaks, Calif. London-based AstraZeneca will give Amgen one-third of the royalties it receives from Allergan.
- The deal is expected to close in the fourth quarter of 2016.
More articles on supply chain:
Supply chain tip of the week: Use data to motivate change
Drugmakers bid on Bayer's dermatology division
3 ways augmented reality devices could improve supply chain